These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 25031041)

  • 21. Abnormal prothrombin (DES-gamma-carboxy prothrombin) in hepatocellular carcinoma.
    Nakao A; Virji A; Iwaki Y; Carr B; Iwatsuki S; Starzl E
    Hepatogastroenterology; 1991 Oct; 38(5):450-3. PubMed ID: 1722483
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated alpha-fetoprotein: differential diagnosis - hepatocellular carcinoma and other disorders.
    Wong RJ; Ahmed A; Gish RG
    Clin Liver Dis; 2015 May; 19(2):309-23. PubMed ID: 25921665
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Post-ablation des-gamma-carboxy prothrombin level predicts prognosis in hepatitis B-related hepatocellular carcinoma.
    Lee S; Rhim H; Kim YS; Kang TW; Song KD
    Liver Int; 2016 Apr; 36(4):580-7. PubMed ID: 26503910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Screening for and surveillance of high-risk patients with HBV-related chronic liver disease: promoting the early detection of hepatocellular carcinoma in China.
    Song P; Feng X; Zhang K; Song T; Ma K; Kokudo N; Dong J; Yao L; Tang W
    Biosci Trends; 2013 Feb; 7(1):1-6. PubMed ID: 23524887
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
    Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
    Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Controversies regarding and perspectives on clinical utility of biomarkers in hepatocellular carcinoma.
    Song PP; Xia JF; Inagaki Y; Hasegawa K; Sakamoto Y; Kokudo N; Tang W
    World J Gastroenterol; 2016 Jan; 22(1):262-74. PubMed ID: 26755875
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum peroxiredoxin3 is a useful biomarker for early diagnosis and assessemnt of prognosis of hepatocellular carcinoma in Chinese patients.
    Shi L; Wu LL; Yang JR; Chen XF; Zhang Y; Chen ZQ; Liu CL; Chi SY; Zheng JY; Huang HX; Yu FJ; Lin XY
    Asian Pac J Cancer Prev; 2014; 15(7):2979-86. PubMed ID: 24815434
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Des-γ carboxyprothrombin may not be a good biomarker for hepatocellular carcinoma in those chronically infected with hepatitis B virus with basal core promoter double mutations (T^{1762}, A^{1764}), a prospective study.
    Li GJ; Chen QY; Harrison TJ; Wang XY; Hu LP; Yang QL; Li KW; Fang ZL
    Cancer Biomark; 2017; 18(3):241-248. PubMed ID: 28085009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma.
    Mita Y; Aoyagi Y; Yanagi M; Suda T; Suzuki Y; Asakura H
    Cancer; 1998 May; 82(9):1643-8. PubMed ID: 9576283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Serum alpha-fetoprotein and lens culinaris agglutinin-reactive fraction of alpha-fetoprotein in patients with hepatocellular carcinoma.
    Kuromatsu R; Tanaka M; Tanikawa K
    Liver; 1993 Aug; 13(4):177-82. PubMed ID: 7690873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Des-γ-Carboxyprothrombin Plasma Level in Diagnosis of Hepatocellular Carcinoma in a Chinese Population Undergoing Surgery.
    Feng X; Song P; Bie P; Jiang P; Ma K; Li X; Wang S; Wang Z; Tang W; Zheng S
    Med Sci Monit; 2016 May; 22():1663-72. PubMed ID: 27187589
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein.
    Hamamura K; Shiratori Y; Shiina S; Imamura M; Obi S; Sato S; Yoshida H; Omata M
    Cancer; 2000 Apr; 88(7):1557-64. PubMed ID: 10738213
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatocellular carcinoma tumour markers: current role and expectations.
    Rich N; Singal AG
    Best Pract Res Clin Gastroenterol; 2014 Oct; 28(5):843-53. PubMed ID: 25260312
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy.
    Kudo M
    J Gastroenterol Hepatol; 2010 Mar; 25(3):439-52. PubMed ID: 20370723
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum tumor markers for detection of hepatocellular carcinoma.
    Zhou L; Liu J; Luo F
    World J Gastroenterol; 2006 Feb; 12(8):1175-81. PubMed ID: 16534867
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma.
    Best J; Bilgi H; Heider D; Schotten C; Manka P; Bedreli S; Gorray M; Ertle J; van Grunsven LA; Dechêne A
    Z Gastroenterol; 2016 Dec; 54(12):1296-1305. PubMed ID: 27936479
    [No Abstract]   [Full Text] [Related]  

  • 37. Current status and future prospects of biomarkers in the diagnosis of hepatocellular carcinoma.
    Zhao Y; Gao Q; Pei L; Wang C; Jin L; Liao F
    Int J Biol Markers; 2017 Oct; 32(4):e361-e369. PubMed ID: 28967065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of serum α-fetoprotein-L3% and des-γ carboxyprothrombin markers in cases with misleading hepatocellular carcinoma total α-fetoprotein levels.
    Hadziyannis E; Sialevris K; Georgiou A; Koskinas J
    Oncol Rep; 2013 Feb; 29(2):835-9. PubMed ID: 23174906
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Midkine (MDK) in Hepatocellular Carcinoma: More than a Biomarker.
    Christou C; Stylianou A; Gkretsi V
    Cells; 2024 Jan; 13(2):. PubMed ID: 38247828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
    J Gastroenterol Hepatol; 2002 Jul; 17(7):772-8. PubMed ID: 12121507
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.